The FDA granted Fast Track Designation (FTD) to 64Cu-SAR-bisPSMA for PET imaging of prostate cancer lesions in patients with biochemical recurrence after definitive therapy.
Clarity Pharmaceuticals partners with Nucleus RadioPharma to advance the Phase 3 SECuRE trial of 67Cu-SAR-bisPSMA for metastatic castration-resistant prostate cancer (mCRPC).
Clarity Pharmaceuticals partners with Nucleus RadioPharma to scale up manufacturing of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer.
Clarity Pharmaceuticals' SECuRE trial demonstrates a favorable safety profile for 67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.